- Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
- Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
- Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
- Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
- Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting
- Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024
- Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.177 |
---|---|
High | 0.177 |
Low | 0.1629 |
Bid | 0.1635 |
Offer | 0.17 |
Previous close | 0.1684 |
Average volume | 842.88k |
---|---|
Shares outstanding | 28.80m |
Free float | 23.37m |
P/E (TTM) | -- |
Market cap | 5.39m USD |
EPS (TTM) | -2.87 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 23:30 BST.
More ▼